Go Deep
Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,842 | -2.3 | 1.26 | 0.00 | 75.05 |
| Oct 2026 | 22,929 | -2.2 | 1.17 | 0.00 | 70.01 |
| Oct 2026 | 22,991 | -1.8 | 1.11 | 0.00 | 66.31 |
| Oct 2026 | 23,048 | -1.8 | 1.06 | 0.00 | 63.06 |
| Oct 2026 | 22,934 | -1.9 | 1.17 | 0.00 | 69.62 |
| Oct 2026 | 23,039 | -1.8 | 1.07 | 0.00 | 63.40 |
| Oct 2026 | 23,081 | -1.7 | 1.03 | 0.00 | 60.91 |
Aldeyra Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -5,450,273.0 | -3,452,619.0 | -6,461,507.0 | -7,688,341.0 |
| EPS | -0.1 | -0.1 | — | -0.1 |
Aldeyra Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -33,846,661.0 | -55,851,444.0 | -37,542,510.0 | -62,024,636.0 | — |
| EPS | -0.6 | -0.9 | -0.6 | -1.1 | — |
Aldeyra Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 72,059,317.0 | 104,606,694.0 | 148,326,911.0 | 181,291,657.0 | — |
| Total Liabilities | 27,808,927.0 | 33,601,823.0 | 28,531,881.0 | 30,283,628.0 | — |
| Total Equity | 44,250,390.0 | 71,004,871.0 | 119,795,030.0 | 151,008,029.0 | — |
Owes vs Owns
Aldeyra Therapeutics, Inc. owed $0.20 for every $1 it owned in Jun 2026, up from $0.17 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.20× | 0.39× | 0.32× | 0.19× | 0.17× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Aldeyra Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 97.2%Other assets 2.4%
How it's funded — Dec 2025
Short-term debt 21.2%Other liabilities 17.2%Shareholders' equity 61.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 70.0 | 101.2 | 142.8 | 174.3 |
| Receivables | 0.0 | 0.0 | 0.0 | 3.2 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.3 | 0.3 | 0.5 | 0.3 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 1.7 | 3.2 | 5.0 | 3.5 |
| Liabilities & equity | ||||
| Short-term debt | 15.2 | 0.0 | 15.1 | 0.9 |
| Long-term debt | 0.0 | 15.0 | 0.3 | 14.9 |
| Payables | 0.2 | 0.2 | 1.3 | 0.1 |
| Other liabilities | 12.4 | 18.4 | 11.8 | 14.3 |
| Shareholders' equity | 44.3 | 71.0 | 119.8 | 151.0 |
| Net tangible assets | 44.3 | 71.0 | 119.8 | 151.0 |
Aldeyra Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -33,345,682.0 | -43,208,747.0 | -30,326,128.0 | -56,637,187.0 | — |
| Investing Activities | 47,736,288.0 | -44,915,755.0 | 30,000,000.0 | -29,954,530.0 | — |
| Financing Activities | 1,123,556.0 | -171,422.0 | -1,270,220.0 | 1,220,092.0 | — |